Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients ...Middle East

STOCKHOLM, Sept. 13, 2024 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) announces that the company has received information about clinical cure in a subset of patients in the ongoing North American Phase 3 study for MOB-015 against nail fungus. The number of patients who have achieved...

Hence then, the article about moberg pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients was published today ( Friday 13/09/2024 - 09:25 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients )

Also on site :

• MCSO: Three family members abducted from a Perinton residence on Saturday
• Man suspected of abducting three of his family members from a Perinton residence on Saturday
• How a Tory MP 37 years ago has inspired a Labour MP’s ‘stalking horse’ leadership challenge to Starmer